High-dose olanzapine and prolactin levels

被引:15
作者
Karagianis, JL [1 ]
Baksh, A [1 ]
机构
[1] Mem Univ Newfoundland, St John, NF, Canada
关键词
D O I
10.4088/JCP.v64n1008
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: This study evaluates whether high-dose olanzapine is associated with elevation of serum prolactin levels. Method: Twenty-four patients taking daily doses of olanzapine of 20, 25, 30, and 40 mg for DSM-IV schizophrenia or schizoaffective disorder had serum prolactin levels measured. The patients were all from one author's (J.L.K.'s) clinical practice. The mean duration of olanzapine therapy was 15.3 months at a dose of at least 20 mg/day. Data were gathered in 2000 and 2001. Results: There was no significant correlation between olanzapine dose and prolactin level (Pearson product moment correlation coefficient = 0.09). No significant differences were found between mean prolactin values in each dose group. Conclusion: There was no significant elevation of prolactin with higher doses of olanzapine. Thus, preliminary evidence suggests that using higher doses of olanzapine is generally safe with regard to prolactin levels.
引用
收藏
页码:1192 / 1194
页数:3
相关论文
共 14 条
[1]   Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine [J].
Alfaro, CL ;
Wudarsky, M ;
Nicolson, R ;
Gochman, P ;
Sporn, A ;
Lenane, M ;
Rapoport, JL .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2002, 12 (02) :83-91
[2]   FIRST CLINICAL-EXPERIENCE WITH OLANZAPINE (LY-170053) - RESULTS OF AN OPEN-LABEL SAFETY AND DOSE-RANGING STUDY IN PATIENTS WITH SCHIZOPHRENIA [J].
BALDWIN, DS ;
MONTGOMERY, SA .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 (04) :239-244
[3]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[4]   Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial [J].
Beasley, CM ;
Hamilton, SH ;
Crawford, AM ;
Dellva, MA ;
Tollefson, GD ;
Tran, PV ;
Blin, O ;
Beuzen, JN .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (02) :125-137
[5]  
Biller BMK, 1999, J REPROD MED, V44, P1095
[6]   The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations [J].
Crawford, AMK ;
Beasley, CM ;
Tollefson, GD .
SCHIZOPHRENIA RESEARCH, 1997, 26 (01) :41-54
[7]   The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia [J].
David, SR ;
Taylor, CC ;
Kinon, BJ ;
Breier, A .
CLINICAL THERAPEUTICS, 2000, 22 (09) :1085-1096
[8]  
Delavierre D, 1999, PROG UROL, V9, P1097
[9]   5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia:: A PET investigation [J].
Kapur, S ;
Zipursky, RB ;
Remington, G ;
Jones, C ;
DaSilva, J ;
Wilson, AA ;
Houle, S .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (07) :921-928
[10]   Prolactin and antipsychotic medications: mechanism of action [J].
Petty, RG .
SCHIZOPHRENIA RESEARCH, 1999, 35 :S67-S73